Market Closed -
Nasdaq
04:00:00 2024-07-02 pm EDT
5-day change
1st Jan Change
1,045
USD
-1.17%
-2.48%
+18.94%
Sales 2024 *
13.82B
Sales 2025 *
14.96B
Capitalization
114B
Net income 2024 *
4.04B
Net income 2025 *
4.46B
EV / Sales 2024 *
7.59
x
Net cash position
2024
*
9.08B
Net cash position
2025
*
14.86B
EV / Sales 2025 *
6.63
x P/E ratio 2024 *
31.2
x
P/E ratio 2025 *
27.9
x
Employees
13,677
Yield 2024 *
-
Yield 2025 *
-
Free-Float
78.42%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,190,564, According to a Recent SEC Filing
Jul. 02
MT
Regeneron Gets European Health Agency Committee's Positive Opinion for Conditional Marketing Authorization of Lymphoma Drug Candidate Odronextamab
Jun. 28
MT
Regeneron Wins CHMP Backing of Lymphoma Drug Odronextamab
Jun. 28
DJ
Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Jun. 28
CI
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study
Jun. 27
MT
Regeneron Pharmaceuticals, Inc Announces Dupixent® Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Jun. 26
CI
FDA approves Verona Pharma's therapy for 'smoker's lungs'
Jun. 26
RE
Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia
Jun. 26
RE
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,170 From $1,060, Buy Rating Maintained
Jun. 25
MT
Declaration of Voting Results by Regeneron Pharmaceuticals, Inc
Jun. 20
CI
Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma
Jun. 18
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,596,400, According to a Recent SEC Filing
Jun. 17
MT
JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $1,150 From $1,050
Jun. 17
MT
Regeneron Pharmaceuticals Says 50% of Patients in Multiple Myeloma Therapy Study Achieved Complete Response
Jun. 17
MT
Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma
Jun. 16
CI
More news
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,190,564, According to a Recent SEC Filing
Jul. 02
MT
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,170 From $1,060, Buy Rating Maintained
Jun. 25
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,596,400, According to a Recent SEC Filing
Jun. 17
MT
JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $1,150 From $1,050
Jun. 17
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $25,610,229, According to a Recent SEC Filing
Jun. 13
MT
More recommendations
1 day -1.17%
1 week -1.81%
Current month -0.61%
1 month +6.58%
3 months +7.77%
6 months +18.94%
Current year +18.94%
More quotes
Managers
Title Age Since
Founder
64
88-01-07
Chief Executive Officer
71
88-01-07
Director of Finance/CFO
53
02-12-31
Members of the board
Title Age Since
Director/Board Member
71
10-11-11
Chief Executive Officer
71
88-01-07
Director/Board Member
83
91-05-31
More insiders
Date
Price
Change
Volume
24-07-02
1,045
-1.17%
358,414
24-07-01
1,057
+0.57%
383,195
24-06-28
1,051
+0.02%
750,619
24-06-27
1,051
-1.71%
507,730
24-06-26
1,069
-0.19%
533,679
Delayed Quote
Nasdaq, July 02, 2024 at 04:00 pm EDT
More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
More about the company
Last Close Price
1,057
USD
Average target price
1,051
USD
Spread / Average Target
-0.53%
Consensus
1st Jan change
Capi.
+18.94% 114B +16.44% 122B +19.62% 25.71B -25.37% 19.02B -20.21% 15.83B -20.20% 15.32B -47.37% 14.88B +59.91% 14.82B +4.35% 14.1B +108.13% 10.7B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1